Docoh
Loading...

DRRX Durect

GRANT
Utility
Short duration depot formulations
23 Nov 21
Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time.
Guohua Chen, David T. Priebe
Filed: 26 Sep 19
APP
Utility
Compositions Comprising Antioxidant, Fluid Dispensers, and Methods Involving the Same
28 Oct 21
A composition includes a salt; a polymer; and an antioxidant.
Xiaoping Song, Clarisa Peer, Su Il Yum
Filed: 9 Apr 21
APP
Utility
Biodegradable Drug Delivery Composition
21 Oct 21
The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle.
William Van Osdol, Su Il Yum, Felix Theeuwes, Michael Sekar, John W Gibson, Keith Edward Branham, Huey-Ching L. Su
Filed: 5 Apr 21
GRANT
Utility
Peroxide removal from drug delivery vehicle
10 Aug 21
The present invention is related to methods for lowering peroxide levels in sucrose acetate isobutyrate formulations and to composition used in and formed by such methods.
Gunjan Junnarkar, Michael A. Desjardin, John P. Carr
Filed: 15 Aug 19
APP
Utility
Compositions Comprising 5-CHOLESTEN-3, 25-DIOL, 3-SULFATE (25HC3S) or Pharmaceutically Acceptable Salt Thereof and at Least One Cyclic Oligosaccharide
10 Jun 21
Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided.
Shunlin Ren, Leyuan Xu, Yanxia Ning, Jin Koung Kim, WeiQi Lin, Mee Jean Kim, Andrew R. Miksztal, Hongwei Wu, Min L. Lee, Wilma Tamraz
Filed: 10 Nov 20
APP
Utility
Use of Oxygenated Cholesterol Sulfates (Ocs) to Treat Inflammatory Skin Disease and Skin Lesions
10 Jun 21
Methods of treating and prophylactically treating inflammatory skin diseases and skin lesions are provided.
Shunlin Ren, WeiQi Lin, James E. Brown, Felix Theeuwes, Mee Jean Kim, Andrew R. Miksztal, Hongwei Wu, Min L. Lee, Huey-Ching Su, Wilma Tamraz
Filed: 16 Oct 20
APP
Utility
Radiation-Sterilized Biodegradable Drug Delivery Compositions
6 May 21
The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation.
Michael Sekar, SuIl Yum, Felix Theeuwes, William Van Osdol
Filed: 19 Oct 20
APP
Utility
Depot Formulations
29 Apr 21
Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.
Jeremy C. WRIGHT, Felix THEEUWES, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK
Filed: 5 Oct 20
APP
Utility
Uses of Oxygenated Cholesterol Sulfates (Ocs)
18 Feb 21
Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided.
Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin
Filed: 3 Aug 20
APP
Utility
Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
11 Feb 21
The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent.
Michael Sekar, Felix Theeuwes, Keith Edward Branham, John W. Gibson, James Matriano, Whitney Moro, John Tipton, William Van Osdol, Su Il Yum
Filed: 21 Jul 20
APP
Utility
Compositions and Methods Involving Polymer, Solvent, and High Viscosity Liquid Carrier Material
21 Jan 21
Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent.
Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks Boyd, Christopher M. RUBINO
Filed: 1 Jun 20
APP
Utility
Depot Formulations
9 Dec 20
Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed.
Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
Filed: 18 May 20
APP
Utility
Depot Formulations
11 Nov 20
Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed.
Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
Filed: 26 Apr 20
GRANT
Utility
Uses of oxygenated cholesterol sulfates (OCS)
28 Sep 20
Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided.
Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin
Filed: 27 Mar 19
APP
Utility
Transoral Dosage Forms Comprising Sufentanil and Naloxone
9 Sep 20
The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test.
Su Il Yum, Jaymin Shah, Sung Yun Kwon, Xiaoping Song
Filed: 12 Feb 20
GRANT
Utility
Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
31 Aug 20
The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent.
Michael Sekar, Felix Theeuwes, Keith E Branham, John Gibson, James Matriano, Whitney Moro, John Tipton, William Van Osdol, Su Il Yum
Filed: 1 Feb 18
APP
Utility
Compositions Comprising Oxygenated Cholesterol Sulfate and at Least One of Polyalkylene Glycol, Carboxymethyl Cellulose and Polyoxylglyceride
15 Jul 20
Compositions comprising oxygenated cholesterol sulfates (OCS) are provided.
Andrew R. Miksztal, WeiQi Lin, Mee Jean Kim, Hongwei Wu, Min L. Lee, Wendy Chao
Filed: 31 Jul 17
APP
Utility
Oral Dosage Form with Drug Composition, Barrier Layer and Drug Layer
24 Jun 20
The present disclosure provides dosage forms designed to deliver active pharmaceutical ingredients (APIs) in a controlled release manner.
Su Il Yum, Wendy Chao, Huey-Ching Su, Yen-Fei Chen, Chin-Chih Chiang
Filed: 4 Jul 17
GRANT
Utility
Depot formulations
15 Jun 20
Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed.
Wilma Tamraz, Huey-Ching Su, WeiQi Lin, Kazuhito Yamada, Naoki Matsumoto, Sreenivasu Mudumba, Komei Okabe
Filed: 27 Dec 17
GRANT
Utility
Depot formulations
1 Jun 20
Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed.
Wilma Tamraz, Huey-Ching Su, WeiQi Lin, Kazuhito Yamada, Naoki Matsumoto, Sreenivasu Mudumba, Komei Okabe
Filed: 28 Jun 17
Patents are sorted by USPTO publication date, most recent first